Zydus Share Price in Focus: Receive USFDA Approval for Deflazacort Tablets

On April 15, 2025, Zydus share price is on investors’ radar, reaching a day high of ₹892.75 at 09:55 AM, after opening at ₹892.75 on BSE. The gain in Zydus share price follows the company’s release for approval from the United States Food and Drug Administration (USFDA) on April 11, 2025.

Approval from USFDA

The pharma giant, Zydus Lifesciences Limited on April 11, 2025, received final approval from the USFDA to manufacture Jaythari® (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza ® Tablets, 6 mg, 18 mg, 30 mg, and 36 mg).

About Deflazacort

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Jaythari® (Deflazacort) will be produced at Doppel Farmaceutici S.r.l., Italy facility. The group now has 424 approvals and has so far filed 492* ANDAs since the commencement of the filing process in FY 2003-04.

Also Read: Zydus Acquires Majority Stake in Amplitude Surgical for €256.8 Mn

Zydus 9M FY25 Performance Overview

For the nine months ended December 31, 2024, the company reported a strong financial performance. Revenue from operations rose by 19% year-on-year to ₹167,136 million. Investments in Research & Development amounted to ₹13,756 million, representing 8.2% of total revenues. The company achieved an EBITDA of ₹49,330 million, marking a 31% increase YoY, with the EBITDA margin improving by 270 basis points to 29.5%.

Net profit for the period stood at ₹33,546 million, up 25% over the previous year. Organic capital expenditure for the nine months was ₹8,938 million. On the balance sheet front, the company maintained a robust financial position with a Net Debt to Equity ratio of -0.14x and a Net Debt to EBITDA ratio of -0.47x as of December 31, 2024. It also held a net cash position (negative net debt) of ₹30,916 million at the end of the period.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, said, “We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.